Alnylam Pharmaceuticals
NASDAQ:ALNYBiotechCambridge, MA, United States · Est. 2002 · 1,100 employees
Alnylam Pharmaceuticals is a biopharmaceutical company pioneering the development of RNA interference (RNAi) therapeutics for genetic disorders.
3
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
6
Indications↗
Distinct diseases across all programs
99
Clinical Trials↗
All sponsored trials (all statuses)
41
Orange Book Patents
Across 4 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
3 drugs in development
Approved1
Phase 32
Phase 21
Preclinical1
By Therapeutic Area
top 3
Cardiovascular
250%
Hematology
125%
Neurology
125%
R&D Momentum
62/100
Pipeline Velocity
34/100
Trial Completion Rate
82/100
Pipeline Concentration
38/100
Pipeline Freshness
75/100
Strategic Signals
- ↗Active in Cardiovascular but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Nov 3, 2026
Active, not recruiting
HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Oct 29, 2026
8-K
8-K
Oct 28, 2026
Recruiting
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Oct 27, 2026
Recruiting
HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Adult and Adolescent Female Patients With Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)
Oct 22, 2026
Enrolling by invitation
An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Oct 22, 2026
Recruiting
A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ALN-6222 in Adult Participants With Obesity
Earlier
Oct 21, 2026TrialA Randomized, Double-blind, Placebo-controlled Study Investigating the Effect of ALN-4324 on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus
Oct 21, 2026TrialA Randomized, Double-blind, Placebo-controlled Single Ascending Dose and Open-label Multi-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-APP in Adult Patients With Early-onset Alzheimer's Disease (EOAD)
4 more events
Oct 21, 2026TrialTRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Oct 21, 2026TrialA Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA)
Oct 21, 2026TrialA Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-4285 in Adult Healthy Volunteers
Oct 21, 2026TrialA Phase 1/2, Randomized, Double-blind, Placebo-controlled 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-4324 in Overweight to Obese Adult Healthy Volunteers and Multiple Dose ALN-4324 in Overweight to Obese Patients With Type 2 Diabetes Mellitus (T2DM)
Details
Company Info
Company Overview
$15.0B
Mkt Cap
$492.9M
Revenue
$812.7M
Cash
CEOHelga Oberbauer
Founded2002
Employees1,100
HQCambridge, MA, United States
ExchangeNASDAQ:ALNY
Websitealnylam.com
LinkedInCompany Page
Therapeutic Focus
CardiovascularNeurologyMetabolic & EndocrineRare DiseaseHematologyOther
Recent SEC Filings
8-KOct 29, 2026
8-K
8-KJul 30, 2026
8-K
8-KApr 30, 2026
ALNYLAM PHARMACEUTICALS, INC. (ALNY) (CIK 0001178670)
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular
Hematology
Neurology
Regulatory
Regulatory Timeline
20182 events
FDAAug 10
Onpattro — ONPATTRO
Application NDA210922 (NDA)
FDAAug 10
Onpattro — ONPATTRO
Application NDA210922
20193 events
FDANov 20
Givlaari — GIVLAARI
Application NDA212194 (NDA)
FDANov 20
Givlaari — GIVLAARI
Application NDA212194
FDASep 16
Onpattro — ONPATTRO
Application NDA210922
20202 events
FDANov 23
Oxlumo — OXLUMO
Application NDA214103 (NDA)
FDAApr 17
Onpattro — ONPATTRO
Application NDA210922
20212 events
FDAOct 28
Givlaari — GIVLAARI
Application NDA212194
FDAMay 6
Onpattro — ONPATTRO
Application NDA210922
20222 events
FDAOct 3
Onpattro — ONPATTRO
Application NDA210922
FDAJun 13
Amvuttra — AMVUTTRA
Application NDA215515 (NDA)
20232 events
FDAFeb 10
Givlaari — GIVLAARI
Application NDA212194
FDAJan 13
Onpattro — ONPATTRO
Application NDA210922
20241 event
FDAApr 29
Givlaari — GIVLAARI
Application NDA212194
20263 events
SECOct 29
8-K
Accession: 0001178670-26-000074
SECJul 30
8-K
Accession: 0001178670-26-000060
SECApr 30
ALNYLAM PHARMACEUTICALS, INC. (ALNY) (CIK 0001178670)
Accession: 001-36407
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)